ClinicalTrials.gg
RecruitingNCT06735768Updated Dec 27, 2024

Closed-loop RTMS for Short-term Migraine Prevention

An interventional study of rTMS treatment and Determination of motor hotspot and motor treshold in Migraine Disorders, sponsored by Brightmind.AI. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Brightmind.AI · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Migraine Disorders with a site in Austria — 4 open to participants now, 6 under way, 2 of them phase 3. Migraine Disorders · Austria.

Planned enrollment
15th of 17
88 · median 621
Started
2024
the only one that year
No phase
3 of 20
1 open now
Registered
15th of 20
by date
Lead sponsor
1 of 20
Brightmind.AI

Among the 20 studies in Migraine Disorders with a site in Austria, this one is the 15th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2024, is one of 3 with no phase, and was the 15th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 20 studies in Migraine Disorders with a site in Austria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Migraine Disorders with a site in Austria, or all of them as a file.
02

Study summary

Migraine is a prevalent and debilitating primary headache disorder, where patients suffer from disabling symptoms that usually consist of a moderate to severe headache lasting 4 to 72 hours, nausea and/or vomiting, phonophobia and photophobia. Transcranial magnetic stimulation (TMS) is a noninvasive technique that is considered to be safe. Repetitive TMS (rTMS) might be useful for migraine prophylaxis. However, available studies on the use of rTMS for preventive treatment of migraine are limited. Currently, rTMS is not recommended in the recent guidelines for the treatment of migraine published by the German Neurological Society in 2022.

Therefore, the aim of the current study is to provide reliable data on the short-term effect of rTMS for the prevention of migraine. The investigators will follow the Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition, with the exception of study duration, which will be limited to four weeks of baseline, three sessions of rTMS within a 10-day timeframe and 4 weeks of follow-up as our study aims to examine short-term efficacy.

03

Conditions studied

  • Migraine Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18-65
  • Migraine without aura, migraine with aura or chronic migraine according to the diagnostic criteria of the third edition of the International Classification of Headache Disorders (ICHD-3) - Age of onset before 50 years of age
  • At least 4 migraine days in each of three subsequent 4- week periods preceding the screening period. (Subsequently, the investigators use month synonymous for 4-week periods)
  • At least 4 migraine days during one month of baseline prior to treatment.
  • Ability to distinguish migraine headaches from other headache types (e.g., tension-type headaches)
  • Willing to adhere to the rTMS regimen and able to monitor MD in Migraine diary
  • No changes in medication usage/regime for three months before the start of treatment (incl. use of acute abortion / rescue medication). In case of Erenumab, Fremanezumab, Galcanezumab no changes in usage/regime for six months before the start of treatment. Every medication is reported and documented.
  • No changes in medication usage/regime during the entire study period (i.e., keeping acute intervention protocol as previously handled for the past three months; not introducing new approaches in intervention/ prevention during this time period (such as anti-nausea drugs not previously taken)). Every medication is reported \& documented.
  • Use of a single drug for migraine prophylaxis is permitted as long as the dosage has not been altered within 3 months of starting the study and the dosage must not be altered for the entire duration of the study.
  • No other stimulation techniques.
  • No change in acupuncture, relaxation training, biofeedback, behavioral therapy or other psychological or psychotherapeutic interventions for three months preceding the study and during the entire study period investigator.
  • Ability to read and understand the written information (patient information, migraine diary, CRF and Adverse Events (AE) collecting form)
  • Completed baseline headache diary with missing data on not more than 5 of 28 days.

Exclusion criteria

Exclusion criteria:

  • More than 26 headache days in any of three subsequent months preceding the screening visit.
  • More than 26 headache days during baseline
  • Pregnant persons
  • Usage of Onabotulinumtoxin A for managing chronic migraines.
  • Medication-overuse according to ICHD-3
  • Presence of metals or implanted devices that can be in close proximity the of device (i.e., above the neckline) and can be adversely affected by magnetic fields including:

    • Stents
    • Implanted stimulators
    • Implanted vagus nerve or brain implants incl. deep brain stimulators
    • Implanted electrical devices
    • Cochlear implants for hearing
    • Any magnetic implants
    • Bullet fragments
    • Grenade fragments
  • Presence of heart pacemakers, defibrillator, intracardiac lines or medication pumps
  • Known severe adverse reactions in response to rTMS
  • Patients diagnosed with bipolar disorder, substance use disorders or psychosis
  • Patients with a known medical history, as well as a family history, of seizures.
  • Patients experiencing chronic sleep deprivation
  • Patients with structural CNS disorders such as a brain tumor, stroke, or traumatic brain injury.
  • Patients with chronic tinnitus in the judgement of the investigator
  • Patients with other disorders interfering with the study in the judgement of the investigator.
  • Treatment with another drug or other intervention until the end of the study
  • Botulinum toxin-based infusions for cosmetic reasons at the forehead within a period of six months prior to study inclusion until the final visit.
  • Other pain syndromes
  • Depression or anxiety in the judgement of the investigator as assessed by means of BDI-II (score 20 or above) and DASS-21 (score 14 or above).
  • Severe health risks in the judgement of the investigator. In particular this includes assessing the risk associated with a history of of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Active group

    This group receives rTMS treatment.

    Device: rTMS treatment · Device: Determination of motor hotspot and motor treshold

  • Sham comparator
    Sham group

    This group receives sham treatment.

    Device: Determination of motor hotspot and motor treshold

Interventions

  • DevicerTMS treatment

    Brightmind.AI´s rTMS protocol is applied

  • DeviceDetermination of motor hotspot and motor treshold

    Determination of motor hotspot and motor treshold

06

What researchers measure

Primary outcomes

  1. Monthly migraine days (MMD)

    Mean number of MMD 4 weeks before and 4 weeks after rTMS treatment.

    Time frame: comparing 4 weeks before with 4 weeks after rTMS

Secondary outcomes

  1. 50 percent responder rate

    Responder rate as a reduction in MMD by 50 percent or more.

    Time frame: comparing 4 weeks before with 4 weeks after rTMS

  2. Weekly Migraine days after stimulation.

    Mean

    Time frame: comparing 4 weeks before with 4 weeks after rTMS

  3. Monthly headache days

    Mean number of monthly headache days before and after rTMS treatment.

    Time frame: comparing 4 weeks before with 4 weeks after rTMS

  4. Monthly (4 weeks) days with use of acute medication

    Mean number of monthly days with acute medication usage before and after rTMS treatment.

    Time frame: comparing 4 weeks before with 4 weeks after rTMS

  5. Headache severity

    Mean headache severity of migraine headaches before and after rTMS treatment.

    Time frame: comparing 4 weeks before with 4 weeks after rTMS

  6. Duration of migraine attacks

    Mean duration of migraine attacks before and after rTMS treatment.

    Time frame: comparing 4 weeks before with 4 weeks after rTMS

07

Study locations

1 of 1 sites recruiting
  • Univ.-Klinik für Neurologie, Medizinische Universität Wien
    Vienna, 1010, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jul 2025, 7 months after the start.

Of 50 industry-sponsored interventional studies with no phase under Migraine Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's planned 7 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 16, 2024
StartActual
Dec 9, 2024
Primary completionEst.
Jul 2025
CompletionEst.
Aug 2025
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06735768
Lead sponsor
Brightmind.AI
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Dec 9, 2024
Primary completion
Jul 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Dec 27, 2024

Study contacts

Luca Ticini, PhD
Contact
luca.ticini@brightmind.ai
0043019470414
Gregor Kowarik, PhD
Contact
gregor.kowarik@brightmind.ai
0043019470414
Christian Wöber, Prof., PhD
principal investigator · Medical University Vienna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion